Proving Value with Data: Health Economics and Outcomes for MedTech Marketers
- Daniel Altherr
- Mar 18
- 12 min read
In today’s cost-conscious healthcare environment, data isn’t just a luxury – it’s a mandate. As healthcare systems worldwide transition from volume-based reimbursements to value-based care, MedTech companies must prove that their products deliver clinical benefits and measurable economic value. Hospital committees and procurement teams increasingly demand robust health economics and outcomes data before green-lighting any purchase. In this evidence era, every claim must be backed by hard data, and every outcome must be translated into financial terms.
In this post, I’ll explore how to build a compelling Health Economics and Outcomes Research (HEOR) dossier, integrate key data into your marketing collateral, leverage real-world evidence (RWE), and tailor your messaging for diverse markets in the EMEA region. I’ll also draw insightful parallels from other industries successfully embracing value-based selling. Throughout, you’ll find actionable tips, interactive ideas, and a checklist to help you refine your strategy. Let’s dive in.
1. The Evidence Era: Why Data is Non-Negotiable
A New Standard for Healthcare Procurement
Healthcare decision-makers today are under constant pressure to improve patient outcomes while controlling costs. This pressure has transformed how hospitals, insurers, and procurement teams evaluate new technologies. In the past, a clinician’s anecdote or a product’s flashy features might have been enough to secure a sale. However, with the rise of value-based care, every investment must be justified by measurable improvements in patient outcomes and cost savings.
Industry reports consistently show that the proportion of healthcare spending linked to outcome measures has grown steadily. Decision-makers now require detailed evidence that a device can reduce complications, shorten hospital stays, and ultimately save money over time. For example, consider a device that reduces post-surgical infections by 30%. To a clinician, this figure might be impressive; to a hospital CFO, it translates into thousands of dollars saved per avoided infection – a game changer in budget-sensitive environments.
Data as the Foundation of Trust
The key to winning over sceptical hospital committees is establishing trust through transparency. Hard data – from clinical trials, observational studies, and economic models – is the currency of modern healthcare. When hospital administrators and procurement teams see detailed, quantitative evidence that a device lowers costs and improves patient outcomes, they are far more likely to approve its adoption. In today’s environment, data-driven decision-making isn’t optional; it’s the foundation upon which all value-based selling is built.
2. Building the Case: Crafting a Robust HEOR Dossier
A robust Health Economics and Outcomes Research (HEOR) dossier is your secret weapon. It’s not enough to simply claim that your product is effective; you must build a persuasive narrative that combines clinical efficacy with economic rationale.
Gathering the Evidence
Clinical Trials and Real-World Studies: Start with rigorous clinical trial data. Randomized controlled trials (RCTs) offer a high level of evidence, demonstrating a device’s efficacy under controlled conditions. However, real-world evidence is equally important. Observational studies and post-market surveillance data show how your product performs in everyday clinical settings, capturing the nuances of patient diversity and practice variability. For example, while an RCT might indicate a 25% reduction in complications, real-world studies may reveal that the reduction is even higher in actual practice.
Economic Models: Translating clinical outcomes into economic impact is critical. Use models that calculate the cost per quality-adjusted life year (QALY) to show that your device offers value in clinical terms and financial efficiency. Additionally, models that estimate savings per procedure should be developed. Imagine a device that reduces complications by 30% – if each avoided complication saves the hospital €10,000, that’s a significant saving over thousands of procedures.
Structuring Your Dossier
A comprehensive HEOR dossier should be structured for clarity and ease of use. Consider including the following sections:
Executive Summary: A concise overview of the key clinical and economic benefits.
Clinical Evidence: Summarize RCT results and real-world studies, highlighting statistically significant improvements.
Economic Analysis: Present detailed models such as cost per QALY, savings per procedure, and overall budget impact analyses.
Case Studies: Include real-world examples where your device improved outcomes and reduced costs.
Visual Aids: Utilize charts, graphs, and infographics to represent complex data visually.
Methodology: Clearly explain how the data was gathered and analyzed to ensure credibility and reproducibility.
Telling the Story with Data
It’s not enough to list numbers – you must tell a story. For example, rather than stating, “Our device reduces infection rates by 30%,” illustrate it as follows:
“In a study of 200 patients, Device X led to a 30% reduction in post-surgical infections, translating to a 25% faster recovery time and an average saving of €10,000 per patient. This means that, for every 100 patients treated, hospitals could potentially save over €1 million in avoided complications.”
This narrative approach transforms raw data into a story of impact that resonates with both clinicians and financial decision-makers.
3. Use in Marketing Collateral: Turning Data into Persuasive Messaging
Once you’ve built your HEOR dossier, it’s time to integrate the data into your marketing collateral in a way that captures attention and drives decision-making.
Crafting a Data-Driven Narrative
Your messaging should emphasize the real-world impact of your device. Instead of simply saying, “Device X is effective,” focus on outcomes and economic benefits. For instance:
“Device X has been shown to reduce post-operative infection rates by 30%, leading to a 25% faster recovery time in a study of 200 patients. This improvement enhances patient care and saves hospitals significant costs by reducing length of stay and lowering readmission rates.”
This approach speaks directly to the concerns of different stakeholders:
Clinicians will appreciate the focus on patient outcomes.
Hospital Administrators and CFOs will be drawn to the cost savings and improved efficiency.
Procurement Teams will see a clear, quantifiable rationale for adopting the device.
Visualizing the Data
Interactive visuals are key to engaging your audience. Consider incorporating the following elements into your collateral:
Interactive Dashboards: An online tool where potential customers can input their own data and see customized ROI estimates.
Animated Infographics: Use animated graphs to show before-and-after scenarios, such as reduced infection rates or shorter hospital stays.
Charts and Graphs: Well-designed bar charts, line graphs, and pie charts can succinctly illustrate key metrics and trends.
For example, an infographic could depict the patient journey with and without Device X, highlighting reduced complications, faster recoveries, and overall cost savings. These visuals help break down complex information into digestible pieces, ensuring that even busy hospital executives can quickly grasp the value proposition.
Tailoring Your Messaging to Different Stakeholders
Different decision-makers interpret data differently. Customize your messaging for various audiences:
For Clinicians: Focus on clinical endpoints, such as improved recovery times and lower complication rates.
For Hospital Administrators/CFOs: Highlight economic benefits, such as ROI, cost per QALY, and overall budget impact.
For Procurement Teams: Offer a balanced mix of clinical and economic data, supported by clear visuals that simplify the decision-making process.
For IT/Data Teams (if applicable): Emphasize integration capabilities, data accuracy, and how the device supports continuous monitoring.
By tailoring your narrative, you ensure that your data speaks directly to the needs and concerns of each stakeholder group.
4. Leverage Real-World Evidence: Beyond the Clinical Trial
While clinical trial data is essential, real-world evidence (RWE) offers an additional validation layer. RWE captures the performance of your device in everyday clinical practice, reflecting a broader patient population and diverse clinical environments.
The Importance of Post-Market Surveillance
Post-market surveillance, registries, and observational studies provide valuable insights into how your device performs once it is widely used. These studies can reveal additional benefits that might not have been apparent in controlled clinical trials. For instance, if a device shows a 30% reduction in complications in a trial, RWE might reveal an even greater benefit when deployed across multiple hospitals with varying patient demographics.
Incorporating RWE into Your Value Proposition
To make the most of RWE, integrate it seamlessly into your HEOR dossier and marketing materials. Here’s how:
Regular Updates: Continuously update your dossier as new RWE becomes available. This demonstrates a commitment to transparency and ongoing improvement.
Publish Findings: Present RWE findings at conferences, in peer-reviewed journals, and through case studies. This external validation enhances your credibility.
Interactive Case Studies: Create interactive case studies on your website where visitors can explore detailed outcomes data and see real-world savings. For example, a clickable timeline showing the patient journey before and after device adoption can be a powerful tool.
Visual Representations: To make RWE data easily digestible, use dynamic visuals, such as line charts comparing complication rates over time or before-and-after comparisons.
Even small case series or registry data can serve as powerful testimonials, particularly when consistently showing positive trends across different settings.
Overcoming Resource Challenges
Gathering high-quality RWE can be resource-intensive, especially for smaller companies. Consider partnering with hospitals or leveraging existing registries to collect data. This collaborative approach not only reduces the burden on your company but also fosters a sense of shared commitment to improving patient outcomes. Remember, even limited datasets, if consistent and well-presented, can significantly bolster your case.
5. EMEA Considerations: Tailoring Data for Regional Audiences
While the principles of value-based selling are universal, evidence expectations can vary across regions. In the EMEA market, decision-makers might focus on different economic and clinical metrics compared to their counterparts in the United States.
Adjusting Your Data Presentation for EMEA Markets
For the UK Market: Institutions like the National Institute for Health and Care Excellence (NICE) require rigorous cost-utility analyses. In your collateral, provide detailed breakdowns of cost per QALY and long-term savings that meet NICE’s criteria. Use visuals that simplify these complex analyses, making them accessible even to non-specialists.
For the German Market: German hospitals often focus on the overall impact on their annual budgets. Present your economic data in terms of annual cost savings and reductions in hospital expenditures. A precise, concise budget impact analysis can be very persuasive in this market.
For Emerging Markets in EMEA: In regions where decision-making may rely on more straightforward ROI arguments, focus on immediate cost savings and quick payback periods. Convey the benefits using straightforward, easily understood metrics and visuals.
Although these approaches vary, the underlying message remains: your device delivers real, quantifiable value that improves outcomes and saves money.
6. Cross-Industry Parallels: Learning from Pharma, SaaS, and Industrial Equipment
The drive to prove value with data isn’t unique to MedTech. Several industries have long embraced health economics and outcomes research, offering valuable lessons that MedTech marketers can adopt.
Lessons from Pharmaceuticals and Biotech
Pharmaceutical companies have been at the forefront of leveraging HEOR data to justify high drug prices. Outcomes-based contracts are now common in the pharma industry – agreements where reimbursement is contingent on achieving specific clinical outcomes. Pharma companies invest heavily in collecting both clinical trial data and real-world evidence to build comprehensive dossiers. MedTech marketers can learn from this by investing in robust HEOR dossiers integrating rigorous clinical data with sophisticated economic models. The key takeaway is that transparency and a data-driven narrative can overcome even the most skeptical payers.
Insights from SaaS and Technology
In the world of enterprise software, value-based selling is the norm. SaaS companies rely on detailed analytics, case studies, and interactive ROI calculators to demonstrate how their solutions save time, reduce errors, and boost productivity. Their sales pitches focus on concrete business outcomes, such as reduced processing times or increased revenue. MedTech companies can adopt similar strategies by creating digital tools that allow hospital decision-makers to input their own data and see customized ROI estimates. The emphasis is on turning complex data into actionable insights that directly speak to cost savings and operational improvements.
Industrial Equipment and Servitization
Heavy industry has embraced a concept known as “servitization,” where companies sell outcomes rather than just products. Rolls-Royce, for example, sells “Power by the Hour” for its jet engines – airlines pay for engine uptime rather than owning the engine outright. This model ties revenue directly to performance and reliability, ensuring that the customer’s financial outcomes are directly linked to the supplier’s success. For MedTech, this could translate into device-as-a-service models or outcome-based contracts that transform one-off sales into long-term partnerships with shared risk and reward. The industrial approach teaches us that when you guarantee performance, you also guarantee value.
Digital Health and Healthcare IT
Digital health companies, particularly those involved in telehealth and remote monitoring, are experts in using real-time data to prove value. They often base their revenue models on outcomes – charging only when their solutions demonstrably reduce hospital readmissions or improve patient adherence. These companies invest in robust analytics platforms and use real-time dashboards to monitor performance continuously. MedTech marketers can borrow from this approach by integrating continuous outcome monitoring into their value propositions, thereby reinforcing the ongoing impact of their products.
7. Actionable Checklist: Building a Data-Driven Value Proposition
To help you implement these strategies, here’s a quick-start checklist for building a robust HEOR dossier and integrating data into your marketing efforts:
Gather and Validate Data:
Collect data from randomized controlled trials.
Supplement with real-world evidence from registries and post-market surveillance.
Develop economic models (cost per QALY, savings per procedure, budget impact analyses).
Structure Your HEOR Dossier:
Create an executive summary that highlights key benefits.
Organize clinical evidence, economic analysis, and case studies in clearly labeled sections.
Include visual aids (charts, graphs, infographics) for easy comprehension.
Provide detailed methodology for transparency.
Integrate Data into Marketing Collateral:
Craft a narrative that links clinical outcomes to economic benefits.
Develop interactive dashboards or ROI calculators for customization.
Tailor messaging for different stakeholder groups (clinicians, administrators, procurement).
Leverage Real-World Evidence:
Partner with hospitals to collect ongoing RWE.
Regularly update your dossier with new findings.
Publish and present RWE findings through case studies and conferences.
Tailor Your Approach for EMEA:
For the UK, prepare detailed cost-utility analyses.
For Germany, focus on budget impact and annual cost savings.
For emerging markets, emphasize straightforward ROI metrics.
Learn from Other Industries:
Study pharma’s outcomes-based contracts and robust HEOR practices.
Leverage SaaS interactive tools and clear ROI messaging.
Consider industrial servitization models for long-term, outcome-based partnerships.
Engage and Educate:
Create interactive content (videos, webinars, downloadable tools).
Foster community engagement through social media and LinkedIn groups.
Encourage feedback and share success stories.
8. Looking Ahead: The Data-Driven Future in MedTech
The shift toward value-based selling is not a passing trend; it represents a fundamental change in how healthcare investments are made. MedTech companies that embrace this data-driven approach position themselves not only as technology providers but as strategic partners in healthcare transformation. By proving that your device delivers tangible clinical benefits and significant cost savings, you win trust and secure long-term contracts in a highly competitive market.
As the Evidence Era unfolds, the companies that invest in robust HEOR capabilities, integrate compelling data into their narratives, and leverage real-world evidence will lead the market. They will be the ones who can confidently tell a story not of a product but of improved patient outcomes, operational efficiencies, and financial prudence.
In this evolving landscape, success hinges on your ability to make data engaging and actionable. Visualize your data, personalize your ROI tools, and continuously update your narratives based on new evidence. Remember, every percentage point improvement or euro saved is a testament to the value you deliver – which drives trust and loyalty in value-based care.
9. Conclusion and Call to Action
Embracing the data-driven future is essential for MedTech marketers who want to thrive in today’s value-based healthcare environment. Your ability to prove value with robust health economics and outcomes data is no longer optional – it’s a necessity. By building a comprehensive HEOR dossier, integrating compelling data into your marketing materials, leveraging real-world evidence, and tailoring your messaging for diverse markets, you can transform your sales approach from merely transactional to truly transformational.
I invite you to share your experiences and challenges in building and utilizing HEOR dossiers in the comments below. How have you overcome hurdles in demonstrating ROI to hospital committees? What interactive tools or strategies have helped you win over sceptical decision-makers? Let’s spark a conversation and learn from each other’s successes and setbacks.
If you’re ready to take your value-based selling strategy to the next level, I encourage you to reach out directly for personalized consulting services. Whether you need help refining your HEOR dossier, developing interactive ROI tools, or crafting a data-driven marketing narrative, I’m here to help you transform your approach and achieve measurable success. The future of MedTech belongs to those who prove their value with data – let’s build that future together.
Further Resources
Footnotes / References
Boston Consulting Group (2017). Why Every Medtech Company Needs a Value-Based Strategy. Discusses the transition to value-based models and emphasizes comprehensive health economic evidence as a driver of success.
MedTech Europe & BCG (2020). How Procurement Unlocks Value-Based Healthcare. Explores the growing momentum of value-based procurement in Europe and the need for robust HEOR data to support deals.
Commonwealth Fund (2023). Engaging Primary Care in Value-Based Payment. Provides data on the increasing proportion of healthcare payments tied to outcomes in the U.S.
Deloitte Center for Health Solutions (2020). Value-Based Payment Models Take Hold in Medtech, but Barriers Slow Shift. Outlines contracting models such as outcome guarantees, gain-sharing, and device-as-a-service, along with regulatory challenges.
University of Twente (2023). Exploring Barriers to Value-Based Procurement in Healthcare. Based on interviews with hospital procurement leaders, identifying challenges like trust issues and short-term financial pressures.
The Brand Leader (2025). The Power of ROI Calculators in MedTech Sales. Emphasizes the importance of ROI tools for substantiating clinical and economic claims.
Alpha Sophia (2023). Building an Effective MedTech Sales Strategy in 2025. Provides examples of successful value-based selling and the need for tailored messaging.
Salesforce Blog (2023). What Is Value Selling? Explores value-based selling principles across industries and highlights the importance of outcome-driven narratives.
Richardson Sales Consulting (2021). Healthcare Sales Challenges Research Study. Identifies common hurdles in MedTech sales, reinforcing the need for comprehensive HEOR data.
Frost & Sullivan (2018). Differences in Medtronic versus Boston Scientific’s Approach to Value-Based Selling. Analyzes how leading MedTech companies integrate health economics into their sales strategies.
Boston Consulting Group (2015). Procurement: The Unexpected Driver of Value-Based Health Care. Discusses the impact of value-based procurement on MedTech sales and the role of HEOR data.
Deloitte Center for Health Solutions (2020). MedTech Sales in a Value-Based World: Strategies for Success. Examines how MedTech companies leverage data and service models to succeed in a value-driven market.
(Additional insights were gathered from LinkedIn discussions, Google search trends, and social media conversations, reinforcing the necessity of data-driven value propositions in today’s healthcare environment.)
Comments